Patent intelligence · CA
CA 3161101
TRAITEMENT DE L'HYPOPARATHYROIDISME
TRAITEMENT DE L'HYPOPARATHYROIDISME
Patent details — CA 3161101
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Jul 22, 2021
- Expiration
- Jul 17, 2041
- Applicant
- ASCENDIS PHARMA BONE DISEASES AS [DK]
- CPC classes
- A61K 38/ 29 A I, A61K 47/ 50 A I, A61K/3829, A61K/4722
Quick answer
CA 3161101 (TRAITEMENT DE L'HYPOPARATHYROIDISME) is held by ASCENDIS PHARMA BONE DISEASES AS [DK]. Status: granted. Granted Jul 22, 2021. Expires Jul 17, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASCENDIS PHARMA BONE DISEASES AS [DK]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 29 A I, A61K 47/ 50 A I, A61K/3829, A61K/4722, A61K/4734, A61K/4760
More from ASCENDIS PHARMA BONE DISEASES AS [DK]
Related pharmaceutical patents in our USPTO index.
-
WO 2025051711
TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE
granted -
WO 2024094673
RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH
granted -
US 2023321198
Dosage Regimen for a Controlled-Release PTH Compound
granted -
CA 3230895
TRAITEMENTS AVEC DES COMPOSES PTH A ACTION PROLONGEE
granted -
CA 3192772
AMELIORATION DU BIEN-ETRE PHYSIQUE ET MENTAL DE PATIENTS ATTEINTS D'HYPOPARATHYROIDISME
granted -
US 2020276276
PTH Prodrugs
granted -
CA 3129357
FORMULATIONS PHARMACEUTIQUES LIQUIDES DE CONJUGUES PTH
granted
Frequently asked questions
What is US patent 3161101?
CA 3161101 (TRAITEMENT DE L'HYPOPARATHYROIDISME) is held by ASCENDIS PHARMA BONE DISEASES AS [DK]. Status: granted. Granted Jul 22, 2021. Expires Jul 17, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3161101?
ASCENDIS PHARMA BONE DISEASES AS [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does CA 3161101 expire?
Our index shows an expiration date of Jul 17, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.